GEN Exclusives

More »

GEN News Highlights

More »
Jan 3, 2007

Epix Secures Patent Related to a GPCR Agonist

  • Epix Pharmaceuticals was issued a patent that covers the class of selective 5-HT1A binding compounds, pharmaceutical compositions containing them, and specific compounds, including PRX-00023. Epix is developing PRX-00023 for the treatment of depression.

    “This patent is further validation of Epix’ ability to synthesize and develop novel drugs that modulate promising GPCR drug targets, such as the 5-HT1A receptor,” says Michael G. Kauffman, M.D., Ph.D., CEO.

    With PRX-00023, which entered clinical trials in February 2004, the company is targeting a commercial opportunity for a selective, once-daily agonist of the specific GPCR known as 5-HT1A that avoids the sexual dysfunction and sleep disorders associated with SSRIs, lacks the addictive and sedative effects of the benzodiazepines, and does not have the slow onset, short half-life, and side effects of a chemical class of 5-HT1A agonists called azapirones. “We look forward to continuing to advance the clinical development of PRX-00023 into a Phase IIb clinical trial in major depression in the first half of this year," states Dr. Kauffman.

    In December 2006, Epix entered a strategic worldwide collaboration with GlaxoSmithKline for four of its GPCR targets, including PRX-03140 for the treatment of Alzheimer's disease.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?